Showing 2801-2810 of 5621 results for "".
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-qr-110-for-lebers-congenital-amaurosis-10/2476214/ProQR Therapeutics announced that it has reached agreement with the FDA on the design of a phase 2/3 pivotal trial (ILLUMINATE) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290gene. LCA is the lead
- Exonate Closes £1.5 Million Fundraising Accelerate Development Eye Drop Treatment for Retinal Neovascular Diseaseshttps://modernod.com/news/exonate-closes-1-5-million-fundraising-accelerate-development-eye-drop-treatment-for-retinal-neovascular-diseases/2476222/Exonate announces the successful closing of its fourth financing round, raising £1.5 million. The funds raised will be used to accelerate the development of Exonate’s lead product, an eye drop for the treatment of retinal neovascular diseases. The company continues to make substantial progress an
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Unum Poll Finds 40 Percent of Adults Spend 12+ Hours on Devices Each Dayhttps://modernod.com/news/unum-poll-finds-40-percent-of-adults-spend-12-hours-on-devices-each-day/2476235/It’s the time of year when many Americans resolve to eat healthier, get more exercise or save more money. But a new resolution in this digital-crazed culture should be to give your eyes a break from too much screen time. A recent poll by employee benefits company Unum found that 40 percent of U.S
- Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordershttps://modernod.com/news/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders/2476249/Japan-based Chugai Pharmaceutical announced that the FDA has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NM
- Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese Markethttps://modernod.com/news/nicox-and-ocumension-therapeutics-sign-exclusive-license-agreement-to-develop-and-commercialize-ncx-470-in-the-chinese-market/2479610/Nicox and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 470, targeting patients with glaucoma or ocular hypertension
- RetinaLyze Receives Funding to Detect Diseases Such as Alzheimer’s Using AIhttps://modernod.com/news/retinalyze-receives-funding-to-detect-diseases-such-as-alzheimers-using-ai/2479612/RetinaLyze System A/S (Ltd.), a Denmark-based medical technology company that specializes in retinal imaging screening software, has received funding from The European Regional Development Fund (ERDF) and Central Denmark Region. The funding will be used to explore and develop novel AI-based solut
- University of Dayton Researcher Named on Second Patent for Device to Provide Better Relief for Glaucoma Patientshttps://modernod.com/news/university-of-dayton-researcher-named-on-second-patent-for-device-to-provide-better-relief-for-glaucoma-patients/2479616/Khalid Lafdi, University of Dayton Wright Brothers Endowed Chair in Nanomaterials, was named on a second patent for a medical drainage device mainly for glaucoma patients that also could be used for drainage in the ears, brain, or chest or to provide access to larger veins or arteries, according
- Ophthalmic Investment Funds Led by Retinal Gene Therapy Developershttps://modernod.com/news/ophthalmic-investment-funds-led-by-retinal-gene-therapy-developers/2476147/Ophthalmology remains one of the most active areas of medical technology investment, attracting monies from venture capitalists, public markets, large ophthalmic companies, and private equity. Market Scope just published its 2017/2018 Ophthalmic Deals Book, analyzing recent ophthalmic fund
- Akorn CEO Steps Down After Loss of $4.3 Billion Fresenius Dealhttps://modernod.com/news/akorn-ceo-steps-down-after-loss-of-4-3-billion-fresenius-deal/2476150/Akorn’s CEO stepped down after the Delaware Supreme Court ruled that a rapid downturn in its business was grounds for Fresenius SE to walk away from a $4.3 billion buyout of the generic drugmaker, according to a Bloomberg News